Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
nL-MAPK8-001 in NEDBA (MAPK8IP3 Mutation)
NCT07197294Phase 2Active, not recruiting
- Sponsor
- n-Lorem Foundation
- Start
- Feb 2025
- Primary completion
- Feb 2027
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
A Phase 2 trial of nL-MAPK8-001 in Neurodevelopmental disorder with or without variable brain abnormalities (NEDBA), sponsored by n-Lorem Foundation. Started Feb 2025; status: active, not recruiting.
02
Drugs
nL-MAPK8-001
03
Conditions
Neurodevelopmental disorder with or without variable brain abnormalities (NEDBA)
Beyond the preview
Go deeper on NCT07197294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07197294.